HomeCompareEIGR vs O

EIGR vs O: Dividend Comparison 2026

EIGR yields 115.94% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGR wins by $7.29M in total portfolio value
10 years
EIGR
EIGR
● Live price
115.94%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.32M
Annual income
$2,715,715.87
Full EIGR calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — EIGR vs O

📍 EIGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGR + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGR pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGR
Annual income on $10K today (after 15% tax)
$9,855.07/yr
After 10yr DRIP, annual income (after tax)
$2,308,358.49/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, EIGR beats the other by $2,304,021.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGR + O for your $10,000?

EIGR: 50%O: 50%
100% O50/50100% EIGR
Portfolio after 10yr
$3.68M
Annual income
$1,360,409.31/yr
Blended yield
36.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

EIGR
No analyst data
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGR buys
0
O buys
14
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$O▲ Buy$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002024-02-13
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-11-03
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-10-31
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-09-06
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-08-29
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-06-29
Ro Khanna🏢 House$O▲ Buy$1,001 - $15,0002023-06-26
Ro Khanna🏢 House$O▼ Sell$1,001 - $15,0002023-05-19
Gary Peters🏛 Senate$O▲ Buy$15,001 - $50,0002023-03-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRO
Forward yield115.94%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$7.32M$34.2K
Annual income after 10y$2,715,715.87$5,102.74
Total dividends collected$6.64M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: EIGR vs O ($10,000, DRIP)

YearEIGR PortfolioEIGR Income/yrO PortfolioO Income/yrGap
1← crossover$22,294$11,594.20$10,818$608.16+$11.5KEIGR
2$48,012$24,157.34$11,787$741.68+$36.2KEIGR
3$99,994$48,621.05$12,946$911.00+$87.0KEIGR
4$201,631$94,637.59$14,345$1,127.94+$187.3KEIGR
5$394,091$178,346.07$16,056$1,409.05+$378.0KEIGR
6$747,454$325,775.96$18,171$1,777.83+$729.3KEIGR
7$1,377,237$577,460.92$20,820$2,268.21+$1.36MEIGR
8$2,468,047$994,404.26$24,188$2,929.90+$2.44MEIGR
9$4,306,232$1,665,421.46$28,533$3,837.11+$4.28MEIGR
10$7,323,384$2,715,715.87$34,235$5,102.74+$7.29MEIGR

EIGR vs O: Complete Analysis 2026

EIGRStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Full EIGR Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this EIGR vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGR vs SCHDEIGR vs JEPIEIGR vs KOEIGR vs MAINEIGR vs STAGEIGR vs ADCEIGR vs NNNEIGR vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.